Casdin Eli 4

What Happened Eli Casdin (reported as a 10% owner) received two equity awards from Standard BioTools: 99,116 restricted stock units (RSUs) and 175,923 RSU-style derivative awards, both reported as acquisitions on June 18, 2026. Both awards are reported at $0.00 per share (no cash paid). Footnote F1 states these RSUs vest in full on the earlier of June 18, 2027 or one day before the company’s next annual meeting, subject to Casdin’s continued service.

Key Details

• Transaction date: 2026-06-18 (Form 4 filed 2026-06-23). Filing appears to be late by one business day vs. the 2-business-day Form 4 deadline.
• Transaction type/code: Grant/Award (A).
• Amounts: 99,116 RSUs (acquired) and 175,923 derivative RSUs (acquired).
• Reported price/value: $0.00 per share; no cash paid on grant.
• Vesting: See F1 — RSUs vest in full on earlier of 6/18/2027 or one day before next annual meeting, subject to continued service.
• Shares owned after transaction: Not specified in this Form 4.
• Other footnotes: F2–F4 note certain securities are held by Casdin-managed funds and may be indirectly beneficially owned; F5 references a separate option vesting schedule.
• Remarks: The filer disclaims beneficial ownership except to the extent of any pecuniary interest.

Context These awards are compensation-style RSUs (a derivative right to receive shares at vesting), not open-market purchases or sales—so they do not signal an immediate buy or sell. For retail investors, RSU grants show management/insider alignment with shareholder value over the vesting period but are routine for compensation. As a reported 10% owner and managing member of Casdin-affiliated entities, some holdings are held through funds, per the filing’s footnotes; this filing reports personal awards rather than an open-market investment.